Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""DEOXYCYTIDINE"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 4738
Tytuł:
EGR1 mediates MDR1 transcriptional activity regulating gemcitabine resistance in pancreatic cancer.
Autorzy:
Yang Z; Department of Gastroenterology, Guangxi Medical University Cancer Hospital, No 71 Hedi Road, Nanning, Guangxi Zhuang Autonomous Region, PR China.
Chen F; Department of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, No 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, PR China.
Wei D; Department of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, No 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, PR China.
Chen F; Department of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, No 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, PR China.
Jiang H; Department of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, No 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, PR China. .
Qin S; Department of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, No 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, PR China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Feb 26; Vol. 24 (1), pp. 268. Date of Electronic Publication: 2024 Feb 26.
Typ publikacji:
Journal Article
MeSH Terms:
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/genetics
Pancreatic Neoplasms*/metabolism
Carcinoma, Pancreatic Ductal*/drug therapy
Carcinoma, Pancreatic Ductal*/genetics
Carcinoma, Pancreatic Ductal*/pathology
Animals ; Humans ; Gemcitabine ; Deoxycytidine/pharmacology ; Deoxycytidine/therapeutic use ; Drug Resistance, Neoplasm/genetics ; Cell Line, Tumor ; Apoptosis ; Early Growth Response Protein 1/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Cannabigerol Induces Autophagic Cell Death by Inhibiting EGFR-RAS Pathways in Human Pancreatic Ductal Adenocarcinoma Cell Lines.
Autorzy:
Zeppa L; School of Pharmacy, University of Camerino, Via Madonna delle Carceri 9, 62032 Camerino, MC, Italy.; Integrative Therapy Discovery Lab, University of Camerino, 62032 Camerino, MC, Italy.
Aguzzi C; School of Pharmacy, University of Camerino, Via Madonna delle Carceri 9, 62032 Camerino, MC, Italy.; Integrative Therapy Discovery Lab, University of Camerino, 62032 Camerino, MC, Italy.
Morelli MB; School of Pharmacy, University of Camerino, Via Madonna delle Carceri 9, 62032 Camerino, MC, Italy.; Integrative Therapy Discovery Lab, University of Camerino, 62032 Camerino, MC, Italy.
Marinelli O; School of Pharmacy, University of Camerino, Via Madonna delle Carceri 9, 62032 Camerino, MC, Italy.; Integrative Therapy Discovery Lab, University of Camerino, 62032 Camerino, MC, Italy.
Giangrossi M; School of Pharmacy, University of Camerino, Via Madonna delle Carceri 9, 62032 Camerino, MC, Italy.
Luongo M; 'Maria Guarino' Foundation-AMOR No Profit Association, 80078 Pozzuoli, NA, Italy.
Amantini C; School of Bioscience and Veterinary Medicine, University of Camerino, 62032 Camerino, MC, Italy.
Santoni G; School of Pharmacy, University of Camerino, Via Madonna delle Carceri 9, 62032 Camerino, MC, Italy.
Nabissi M; School of Pharmacy, University of Camerino, Via Madonna delle Carceri 9, 62032 Camerino, MC, Italy.; Integrative Therapy Discovery Lab, University of Camerino, 62032 Camerino, MC, Italy.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 07; Vol. 25 (4). Date of Electronic Publication: 2024 Feb 07.
Typ publikacji:
Journal Article
MeSH Terms:
Autophagic Cell Death*/drug effects
Cannabinoids*/pharmacology
Carcinoma, Pancreatic Ductal*/drug therapy
Carcinoma, Pancreatic Ductal*/genetics
Carcinoma, Pancreatic Ductal*/metabolism
Pancreatic Neoplasms*/metabolism
Humans ; Apoptosis ; Cell Line, Tumor ; Deoxycytidine/pharmacology ; Deoxycytidine/therapeutic use ; ErbB Receptors/antagonists & inhibitors ; Proto-Oncogene Proteins p21(ras)/antagonists & inhibitors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Identification and Clinical Significance of Pancreatic Cancer Stem Cells and Their Chemotherapeutic Drug Resistance.
Autorzy:
Kuo YC; Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, Lin-Kou, Taoyuan 333, Taiwan.
Kou HW; Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, Lin-Kou, Taoyuan 333, Taiwan.
Hsu CP; Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, Lin-Kou, Taoyuan 333, Taiwan.
Lo CH; Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, Lin-Kou, Taoyuan 333, Taiwan.
Hwang TL; Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, Lin-Kou, Taoyuan 333, Taiwan.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Apr 15; Vol. 24 (8). Date of Electronic Publication: 2023 Apr 15.
Typ publikacji:
Journal Article
MeSH Terms:
Deoxycytidine*/pharmacology
Deoxycytidine*/therapeutic use
Pancreatic Neoplasms*/metabolism
Male ; Humans ; Epithelial Cell Adhesion Molecule/metabolism ; Clinical Relevance ; Gemcitabine ; Drug Resistance, Multiple ; Neoplastic Stem Cells/metabolism ; Cell Line, Tumor ; Drug Resistance, Neoplasm ; Epithelial-Mesenchymal Transition ; Pancreatic Neoplasms
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
[Gemcitabine long-term maintenance chemotherapy benefits patients with survival: a multicenter, real-world study of advanced breast cancer treatment in China].
Autorzy:
Yue J; Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Song GH; Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Li HP; Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Sun T; Department of Breast Medicine, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang 110042, China.
Song LH; Department of Medical Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.
Tong ZS; Department of Breast Oncology, Tianjin Medical University Cancer Hospital, National Clinical Research Center of Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
Zhang LL; Department of Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, China.
Song ZC; Breast Cancer, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Ouyang QC; Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital, Changsha 410006, China.
Yang J; Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710049, China.
Pan YY; Department of Medical Oncology, Provincial Hospital Affiliated to Anhui Medical University, Hefei 230001, China.
Yuan P; Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Pokaż więcej
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2024 Mar 23; Vol. 46 (3), pp. 249-255.
Typ publikacji:
Multicenter Study; English Abstract; Journal Article
MeSH Terms:
Breast Neoplasms*/pathology
Gemcitabine*
Female ; Humans ; Middle Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Deoxycytidine/therapeutic use ; Maintenance Chemotherapy ; Treatment Outcome ; Adult ; Aged
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Gemcitabine Modulates HLA-I Regulation to Improve Tumor Antigen Presentation by Pancreatic Cancer Cells.
Autorzy:
Larson AC; Eppley Institute for Research in Cancer & Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Knoche SM; Eppley Institute for Research in Cancer & Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Brumfield GL; Eppley Institute for Research in Cancer & Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Doty KR; Eppley Institute for Research in Cancer & Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Gephart BD; Eppley Institute for Research in Cancer & Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Moore-Saufley PR; Departments of Psychology and Biology, University of Nebraska Omaha, Omaha, NE 68192, USA.
Solheim JC; Eppley Institute for Research in Cancer & Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Mar 11; Vol. 25 (6). Date of Electronic Publication: 2024 Mar 11.
Typ publikacji:
Journal Article
MeSH Terms:
Gemcitabine*
Pancreatic Neoplasms*/metabolism
Humans ; Deoxycytidine/therapeutic use ; Antigen Presentation ; Histocompatibility Antigens Class I/genetics ; Peptides ; Antigens, Neoplasm/therapeutic use ; Pancreatic Hormones ; Cell Line, Tumor
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials.
Autorzy:
Huan L; Department of Hepatopancreatobiliary Surgery, Chongqing Fifth People's Hospital, Chongqing, Chongqing, China.
Yu F; Department of Hepatopancreatobiliary Surgery, Chongqing Fifth People's Hospital, Chongqing, Chongqing, China.
Cao D; Department of Hepatopancreatobiliary Surgery, Chongqing Fifth People's Hospital, Chongqing, Chongqing, China.
Zhou H; Department of Hepatopancreatobiliary Surgery, Chongqing Fifth People's Hospital, Chongqing, Chongqing, China.
Qin M; Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China.
Cao Y; Department of Hepatopancreatobiliary Surgery, Chongqing Fifth People's Hospital, Chongqing, Chongqing, China.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Mar 07; Vol. 19 (3), pp. e0295983. Date of Electronic Publication: 2024 Mar 07 (Print Publication: 2024).
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:
Neoadjuvant Therapy*/methods
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/surgery
Humans ; Gemcitabine ; Capecitabine/therapeutic use ; Cisplatin/therapeutic use ; Epirubicin/therapeutic use ; Network Meta-Analysis ; Bayes Theorem ; Randomized Controlled Trials as Topic ; Deoxycytidine/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study.
Autorzy:
Gueiderikh A; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.; Université Paris Saclay, 91471, Orsay, France.
Tarabay A; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.
Abdelouahab M; Département de statistiques, Gustave Roussy, 94800, Villejuif, France.
Smolenschi C; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.; Gustave Roussy, DITEP, 94800, Villejuif, France.
Tanguy ML; Département de statistiques, Gustave Roussy, 94800, Villejuif, France.
Valery M; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.
Malka D; Département d'oncologie médicale, Institut Mutualiste Montsouris, 75014, Paris, France.
Pudlarz T; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.
Fuerea A; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.
Boige V; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.
Hollebecque A; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.; Gustave Roussy, DITEP, 94800, Villejuif, France.
Ducreux M; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France.; Université Paris Saclay, 91471, Orsay, France.
Boilève A; Département de médecine oncologique, Gustave Roussy, 94800, Villejuif, France. .; Université Paris Saclay, 91471, Orsay, France. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Feb 26; Vol. 24 (1), pp. 272. Date of Electronic Publication: 2024 Feb 26.
Typ publikacji:
Journal Article
MeSH Terms:
Pancreatic Neoplasms*/pathology
Adenocarcinoma*/pathology
Humans ; Gemcitabine ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Retrospective Studies ; Erlotinib Hydrochloride/therapeutic use ; Deoxycytidine ; Fluorouracil ; Leucovorin/therapeutic use ; Paclitaxel ; Albumins
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
First-in-Class Humanized Antibody against Alternatively Spliced Tissue Factor Augments Anti-Metastatic Efficacy of Chemotherapy in a Preclinical Model of Pancreatic Ductal Adenocarcinoma.
Autorzy:
Lewis CS; Division of Hematology/Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
Backman C; Division of Hematology/Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
Ahsan S; Division of Hematology/Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
Cliff A; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Hariharan A; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Yeh JJ; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.; Departments of Surgery and Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Zhang X; Division of Environmental Genetics and Molecular Toxicology, Department of Environmental and Public Health Sciences, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
Xie C; Division of Biostatistics and Bioinformatics, Department of Environmental and Public Health Sciences, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
Sohal DPS; Division of Hematology/Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
Bogdanov VY; Division of Hematology/Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 23; Vol. 25 (5). Date of Electronic Publication: 2024 Feb 23.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Pancreatic Ductal*/pathology
Pancreatic Neoplasms*/pathology
Humans ; Thromboplastin ; Gemcitabine ; Antibodies, Monoclonal, Humanized/therapeutic use ; Leukocytosis/drug therapy ; Cell Line, Tumor ; Deoxycytidine/pharmacology ; Paclitaxel/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effectiveness of azvudine in reducing mortality of COVID-19 patients: a systematic review and meta-analysis.
Autorzy:
Wang Y; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing, Dongcheng District, 100730, Beijing, China.
Xie H; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing, Dongcheng District, 100730, Beijing, China.
Wang L; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing, Dongcheng District, 100730, Beijing, China.
Fan J; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing, Dongcheng District, 100730, Beijing, China.
Zhang Y; International Medical Services, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Pan S; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing, Dongcheng District, 100730, Beijing, China.
Zhou W; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing, Dongcheng District, 100730, Beijing, China.
Chen Q; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing, Dongcheng District, 100730, Beijing, China.
Liu X; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing, Dongcheng District, 100730, Beijing, China.
Wu A; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing, Dongcheng District, 100730, Beijing, China.
Zhang H; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing, Dongcheng District, 100730, Beijing, China.
Wang J; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing, Dongcheng District, 100730, Beijing, China.
Tian X; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing, Dongcheng District, 100730, Beijing, China. .
Pokaż więcej
Źródło:
Virology journal [Virol J] 2024 Feb 23; Vol. 21 (1), pp. 46. Date of Electronic Publication: 2024 Feb 23.
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article; Review
MeSH Terms:
COVID-19*
Azides*
Deoxycytidine/*analogs & derivatives
Humans ; Cohort Studies ; China ; Databases, Factual
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma.
Autorzy:
Zhang J; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Yang M; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Wei D; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Zhang D; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Chen Z; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. .
Zhu H; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Feb 13; Vol. 24 (1), pp. 202. Date of Electronic Publication: 2024 Feb 13.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Transitional Cell*/drug therapy
Carcinoma, Transitional Cell*/surgery
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/surgery
Antibodies, Monoclonal, Humanized*
Humans ; Cisplatin/therapeutic use ; Gemcitabine ; Retrospective Studies ; Deoxycytidine/adverse effects ; Muscles ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study.
Autorzy:
Chen MP; Department of Infectious Disease, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University (The First Hospital of Changsha), Changsha, 410000, People's Republic of China.
Jiang DX; Department of Respiratory and Critical Care Medicine, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University (The First Hospital of Changsha), Changsha, 410000, People's Republic of China.
Rang JX; Department of Nurse, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University (The First Hospital of Changsha), Changsha, 410000, People's Republic of China.
Zhuo HB; Department of Respiratory and Critical Care Medicine, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University (The First Hospital of Changsha), Changsha, 410000, People's Republic of China.
Zhou ZG; Department of Respiratory and Critical Care Medicine, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University (The First Hospital of Changsha), Changsha, 410000, People's Republic of China. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Feb 09; Vol. 14 (1), pp. 3318. Date of Electronic Publication: 2024 Feb 09.
Typ publikacji:
Journal Article
MeSH Terms:
Ritonavir*/therapeutic use
COVID-19*
Hydroxylamines*
Nitriles*
Lactams*
Proline*
Azides*
Leucine*
Deoxycytidine/*analogs & derivatives
Cytidine/*analogs & derivatives
Adult ; Humans ; Retrospective Studies ; COVID-19 Drug Treatment ; Antiviral Agents/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A new technique for the analysis of metabolic pathways of cytidine analogues and cytidine deaminase activities in cells.
Autorzy:
Ligasová A; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic. .
Piskláková B; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic.; Laboratory of Inherited Metabolic Disorders, Department of Clinical Chemistry, Palacký University and University Hospital Olomouc, Olomouc, Czech Republic.
Friedecký D; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic.; Laboratory of Inherited Metabolic Disorders, Department of Clinical Chemistry, Palacký University and University Hospital Olomouc, Olomouc, Czech Republic.
Koberna K; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Nov 22; Vol. 13 (1), pp. 20530. Date of Electronic Publication: 2023 Nov 22.
Typ publikacji:
Journal Article
MeSH Terms:
Cytidine*/metabolism
DCMP Deaminase*
Deoxycytidine Kinase/genetics ; Deoxycytidine Kinase/metabolism ; Deoxycytidine ; Metabolic Networks and Pathways ; Cytidine Deaminase/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Preclinical evaluation of pentagamavunone-1 as monotherapy and combination therapy for pancreatic cancer in multiple xenograft models.
Autorzy:
Kamitani N; Department of Surgery, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan.
Nakamae I; Laboratory of Tumor Cell Biology, Division of Biological Science, Graduate School of Science and Technology, Nara Institute of Science and Technology, 8916-5, Takayama, Ikoma, Nara, 630-0101, Japan.
Yoneda-Kato N; Laboratory of Tumor Cell Biology, Division of Biological Science, Graduate School of Science and Technology, Nara Institute of Science and Technology, 8916-5, Takayama, Ikoma, Nara, 630-0101, Japan.
Kato JY; Laboratory of Tumor Cell Biology, Division of Biological Science, Graduate School of Science and Technology, Nara Institute of Science and Technology, 8916-5, Takayama, Ikoma, Nara, 630-0101, Japan. .
Sho M; Department of Surgery, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Dec 27; Vol. 12 (1), pp. 22419. Date of Electronic Publication: 2022 Dec 27.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Deoxycytidine*/pharmacology
Deoxycytidine*/therapeutic use
Pancreatic Neoplasms*/pathology
Humans ; Mice ; Animals ; Heterografts ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Gemcitabine ; Cell Proliferation ; Apoptosis ; Xenograft Model Antitumor Assays ; Cell Line, Tumor ; Pancreatic Neoplasms
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Optimal treatment occasion for ultrasound stimulated microbubbles in promoting gemcitabine delivery to VX2 tumors.
Autorzy:
Luo T; Department of Ultrasound, Xinqiao Hospital, Army Medical University, Chongqing, China.
Bai L; Department of Ultrasound, Xinqiao Hospital, Army Medical University, Chongqing, China.
Zhang Y; Department of Ultrasound, Xinqiao Hospital, Army Medical University, Chongqing, China.
Huang L; Department of Ultrasound, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, China.
Li H; Department of Ultrasound, Xinqiao Hospital, Army Medical University, Chongqing, China.
Gao S; Department of Ultrasound, General Hospital of Central Theatre Command, Wuhan, China.
Dong X; Department of Ultrasound, Xinqiao Hospital, Army Medical University, Chongqing, China.
Li N; Department of Ultrasound, Xinqiao Hospital, Army Medical University, Chongqing, China.
Liu Z; Department of Ultrasound, Xinqiao Hospital, Army Medical University, Chongqing, China.
Pokaż więcej
Źródło:
Drug delivery [Drug Deliv] 2022 Dec; Vol. 29 (1), pp. 2796-2804.
Typ publikacji:
Journal Article
MeSH Terms:
Deoxycytidine*/analogs & derivatives
Deoxycytidine*/pharmacology
Microbubbles*
Animals ; Cell Line, Tumor ; Rabbits ; Ultrasonography ; Gemcitabine
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells.
Autorzy:
Bergonzini C; Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.
Gregori A; Physics of Life Processes, Leiden Institute of Physics, Leiden University, Leiden, The Netherlands.; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, VU University, Amsterdam, The Netherlands.
Hagens TMS; Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.
van der Noord VE; Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.
van de Water B; Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.
Zweemer AJM; Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.
Coban B; Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.
Capula M; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, VU University, Amsterdam, The Netherlands.; Cancer Pharmacology Lab, Fondazione Pisana Per La Scienza, San Giuliano, Pisa, Italy.
Mantini G; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, VU University, Amsterdam, The Netherlands.
Botto A; Proteomics and Metabolomics Lab, Fondazione Pisana Per La Scienza, San Giuliano, Pisa, Italy.; Department of Chemistry and Industrial Chemistry, University of Pisa, Pisa, Italy.
Finamore F; Proteomics and Metabolomics Lab, Fondazione Pisana Per La Scienza, San Giuliano, Pisa, Italy.
Garajova I; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
McDonnell LA; Proteomics and Metabolomics Lab, Fondazione Pisana Per La Scienza, San Giuliano, Pisa, Italy.
Schmidt T; Physics of Life Processes, Leiden Institute of Physics, Leiden University, Leiden, The Netherlands.
Giovannetti E; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, VU University, Amsterdam, The Netherlands. .; Cancer Pharmacology Lab, Fondazione Pisana Per La Scienza, San Giuliano, Pisa, Italy. .
Danen EHJ; Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands. .
Pokaż więcej
Źródło:
Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2024 Jan 02; Vol. 43 (1), pp. 4. Date of Electronic Publication: 2024 Jan 02.
Typ publikacji:
Journal Article
MeSH Terms:
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/genetics
Pancreatic Neoplasms*/metabolism
Carcinoma, Pancreatic Ductal*/drug therapy
Carcinoma, Pancreatic Ductal*/genetics
Carcinoma, Pancreatic Ductal*/pathology
Humans ; Paclitaxel/pharmacology ; Paclitaxel/therapeutic use ; Gemcitabine ; Deoxycytidine/pharmacology ; Deoxycytidine/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; ATP Binding Cassette Transporter, Subfamily B/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Clinical Study of Anti-PD-1 Immunotherapy Combined with Gemcitabine Chemotherapy in Multiline Treatment of Advanced Pancreatic Cancer.
Autorzy:
Liu Y; General Surgery Department, The Second Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi 710038, China.
Li Y; Gynaecology and Obstetrics Department, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710068, China.
Du S; Gastroenterology Department, The Second Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi 710038, China.
Fan L; Gastroenterology Department, The Second Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi 710038, China.
Wang J; Gastroenterology Department, The Second Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi 710038, China.
Pokaż więcej
Źródło:
Computational and mathematical methods in medicine [Comput Math Methods Med] 2022 Sep 06; Vol. 2022, pp. 4070060. Date of Electronic Publication: 2022 Sep 06 (Print Publication: 2022).
Typ publikacji:
Journal Article; Retracted Publication
MeSH Terms:
C-Reactive Protein*
Deoxycytidine*/analogs & derivatives
Deoxycytidine*/therapeutic use
Immunotherapy*
Pancreatic Neoplasms*/drug therapy
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinoembryonic Antigen ; Fatigue ; Humans ; Retrospective Studies ; Gemcitabine ; Pancreatic Neoplasms
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A pilot study investigating plasma pharmacokinetics and tolerance of oral capecitabine in carcinoma-bearing dogs.
Autorzy:
Wetzel S; Previously affiliated with the College of Veterinary Medicine, Washington State University, Pullman, WA, USA. .; Currently associated with SASH (Small Animal Specialist Hospital), North Ryde, NSW, Australia. .
Fidel J; College of Veterinary Medicine, Washington State University, Pullman, WA, USA.
Whittington D; School of Pharmacy, University of Washington, Seattle, WA, USA.
Villarino NF; College of Veterinary Medicine, Washington State University, Pullman, WA, USA.
Pokaż więcej
Źródło:
BMC veterinary research [BMC Vet Res] 2024 Jan 31; Vol. 20 (1), pp. 36. Date of Electronic Publication: 2024 Jan 31.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma*/drug therapy
Carcinoma*/veterinary
Dog Diseases*/etiology
Dogs ; Humans ; Animals ; Capecitabine/therapeutic use ; Pilot Projects ; Deoxycytidine/adverse effects ; Fluorouracil/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Administration, Oral
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy and safety of azvudine in symptomatic adult COVID-19 participants who are at increased risk of progressing to critical illness: a study protocol for a multicentre randomized double-blind placebo-controlled phase III trial.
Autorzy:
Tian X; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Xu Y; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Wang L; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Dong C; Department of Biostatistics, Peking University First Hospital, Beijing, China.
Yan X; Peking University Clinical Research Institute, Beijing, China.
Fan J; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Xie H; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Zhang H; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Wang J; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Liu Y; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Wang Y; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Pan S; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Wu A; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Liu X; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Yao C; Peking University Clinical Research Institute, Beijing, China.; Department of Biostatistics, Peking University First Hospital, Beijing, China.
Wang M; Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China. .
Pokaż więcej
Źródło:
Trials [Trials] 2024 Jan 22; Vol. 25 (1), pp. 77. Date of Electronic Publication: 2024 Jan 22.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
COVID-19*
Azides*
Deoxycytidine/*analogs & derivatives
Adult ; Humans ; Critical Illness ; SARS-CoV-2 ; Antiviral Agents/adverse effects ; Randomized Controlled Trials as Topic ; Multicenter Studies as Topic ; Clinical Trials, Phase III as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Survival outcome of different treatment sequences in patients with locally advanced and metastatic pancreatic cancer.
Autorzy:
Fan M; Medical School of Chinese People's Liberation Army, Beijing, China.; Department of oncology, The Fifth Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China.; Department of oncology, The First Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China.
Deng G; Department of oncology, The Fifth Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China.
Ma Y; Medical School of Chinese People's Liberation Army, Beijing, China.; Department of oncology, The Fifth Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China.
Si H; Department of oncology, The Fifth Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China.
Wang Z; Department of oncology, The Fifth Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China. .
Dai G; Department of oncology, The Fifth Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Jan 12; Vol. 24 (1), pp. 67. Date of Electronic Publication: 2024 Jan 12.
Typ publikacji:
Journal Article
MeSH Terms:
Pancreatic Neoplasms*/pathology
Humans ; Gemcitabine ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Deoxycytidine ; Retrospective Studies ; Fluorouracil ; Paclitaxel ; Leucovorin ; Albumins
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Comparison of different Pancreatic cancer treatments: a three-year retrospective study in the oncology center of Tangier university hospital, Morocco.
Autorzy:
Abrini H; Department of Medical Oncology, Faculty of Medicine and Pharmacy, Ahmad Bin Zayed Al Nahyan Center of Cancer Treatment, Mohammed VI University Hospital of Tangier, Abdelmalek Essaadi University, Tangier, Morocco. .
Amzerin M; Department of Medical Oncology, Faculty of Medicine and Pharmacy, Ahmad Bin Zayed Al Nahyan Center of Cancer Treatment, Mohammed VI University Hospital of Tangier, Abdelmalek Essaadi University, Tangier, Morocco.
El Baaboua A; Biotechnology and Applied Microbiology Team, Department of Biology, Faculty of Sciences, Abdelmalek-Essaadi University, Tetouan, Morocco.
Aboulaghras S; Physiology and Physiopathology Team, Genomic of Human Pathologies Research, Faculty of Sciences, Mohammed V University, Rabat, Morocco.
Bouhda A; Department of Medical Oncology, Faculty of Medicine and Pharmacy, Ahmad Bin Zayed Al Nahyan Center of Cancer Treatment, Mohammed VI University Hospital of Tangier, Abdelmalek Essaadi University, Tangier, Morocco.
El Mrabet FZ; Department of Medical Oncology, Faculty of Medicine and Pharmacy, Ahmad Bin Zayed Al Nahyan Center of Cancer Treatment, Mohammed VI University Hospital of Tangier, Abdelmalek Essaadi University, Tangier, Morocco.
Pokaż więcej
Źródło:
BMC gastroenterology [BMC Gastroenterol] 2023 Dec 21; Vol. 23 (1), pp. 452. Date of Electronic Publication: 2023 Dec 21.
Typ publikacji:
Journal Article
MeSH Terms:
Pancreatic Neoplasms*/drug therapy
Humans ; Female ; Male ; Middle Aged ; Aged ; Gemcitabine ; Retrospective Studies ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Deoxycytidine/therapeutic use ; Morocco/epidemiology ; Fluorouracil/therapeutic use ; Leucovorin/therapeutic use ; Hospitals
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 4738

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies